As filed with the Securities and Exchange Commission on April 4, 2007
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ACADIA PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| Delaware | 06-1376651 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
3911 Sorrento Valley Boulevard
San Diego, California 92121
(858) 558-2871
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Uli Hacksell, Ph.D.
Chief Executive Officer
3911 Sorrento Valley Boulevard
San Diego, California 92121
(858) 558-2871
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
| Glenn F. Baity General Counsel ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard San Diego, California 92121 (858) 558-2871 |
D. Bradley Peck J. Patrick Loofbourrow Cooley Godward Kronish LLP 4401 Eastgate Mall San Diego, California 92121-9109 (858 550-6000 |
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration Statement.
If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. x
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x 333-139217
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Calculation of Registration Fee
| Title of Class of Securities to be Registered | Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee (1) | ||||
| Common Stock, $0.0001 par value |
$2,493,750 | $76.56 | ||||
| (1) | The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act under the Securities Act of 1933. |
EXPLANATORY NOTE
This registration statement is being filed to register an additional $2,493,750 worth of shares of our common stock, $0.0001 par value per share, pursuant to Rule 462(b) of the Securities Act of 1933, as amended. In accordance with Rule 462(b), this registration statement incorporates by reference the contents of our registration statement on Form S-3 (File No. 333-139217) which was declared effective on December 28, 2006, including all amendments, supplements and exhibits thereto and all information incorporated by reference therein, other than the exhibits included herein.
The required opinions and consents are listed on the Index to Exhibits attached to and filed with this registration statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on April 4, 2007.
| ACADIA Pharmaceuticals Inc. | ||
| By: | /s/ ULI HACKSELL | |
| Uli Hacksell, Chief Executive Officer | ||
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
Title |
Date | ||||
| By: | /s/ ULI HACKSELL Uli Hacksell |
Chief Executive Officer and Director (Principal Executive Officer) |
April 4, 2007 | |||
| By: | /S/ THOMAS H. AASEN Thomas H. Aasen |
Vice President, Chief Financial Officer, Treasurer and Secretary (Principal Financial Officer and Principal Accounting Officer) |
April 4, 2007 | |||
| By: | /S/ * Leslie Iversen |
Chairman of the Board | April 4, 2007 | |||
| By: | /S/ * Gordon Binder |
Director | April 4, 2007 | |||
| By: | /S/ * Michael Borer |
Director | April 4, 2007 | |||
| By: | /S/ * Mary Ann Gray |
Director | April 4, 2007 | |||
| By: | /S/ * Lester Kaplan |
Director | April 4, 2007 | |||
| By: | /S/ * Torsten Rasmussen |
Director | April 4, 2007 | |||
| By: | /S/ * Alan Walton |
Director | April 4, 2007 | |||
| *By: | /S/ ULI HACKSELL | |
| Uli Hacksell Attorney-in-fact | ||
INDEX TO EXHIBITS
| Exhibit Number |
Description of Document | |
| 5.1 | Opinion of Cooley Godward Kronish LLP. | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | |
| 23.2 | Consent of Cooley Godward Kronish LLP (included as Exhibit 5.1 to this filing). | |
| 24.1 | Power of Attorney (incorporated by reference to Exhibit 24.1 to Registration Statement File No. 333-139217). | |